BioNTech investors absorbed a 7.13% loss when the AHEAD-MERIT trial of BNT113 missed its progression-free survival primary endpoint. An investigation is underway into whether the Company's statements about its mRNA oncology programs gave shareholders an accurate picture.
Read on prnewswire.com